Onychomycosis (Tinea Unguium) Drug Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global Onychomycosis (Tinea Unguium) Drug market size was valued at USD 3383.2 million in 2022 and is forecast to a readjusted size of USD 4938 million by 2029 with a CAGR of 5.6% during review period.

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate. Onychomycosis (Tinea Unguium) Drug is the drug for the treatment of this disease.

Global Onychomycosis (Tinea Unguium) Drug key players include Pfizer, J&J, Novartis, Galderma pharm, Valeant Pharma, etc. Global top five manufacturers hold a share about 35%. North America is the largest market, with a share about 30%, followed by Europe and China both have a share over 45 percent. In terms of product, Oral Medication is the largest segment, with a share over 70%. And in terms of application, the largest application is Age above 50, followed by Age under 18.

This report is a detailed and comprehensive analysis for global Onychomycosis (Tinea Unguium) Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Onychomycosis (Tinea Unguium) Drug market size and forecasts, in consumption value ($ Million), 2018-2029
Global Onychomycosis (Tinea Unguium) Drug market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Onychomycosis (Tinea Unguium) Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Onychomycosis (Tinea Unguium) Drug market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Onychomycosis (Tinea Unguium) Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace

This report profiles key players in the global Onychomycosis (Tinea Unguium) Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

   Pfizer
   Yangtze River
   Torrent Pharma
   J&J
   Chengdu Brilliant
   Novartis
   Qilu Pharmaceutical
   Xiuzheng Pharmaceutical
   Hubei Hengan
   TARO
   Perrigo
   Galderma pharm
   Zhejiang Deyer
   Valeant Pharma
   Moberg

   Oral Medication
   External Medicine

   Age under 18
   Age 18-50
   Age above 50

   North America (United States, Canada, and Mexico)
   Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
   South America (Brazil, Argentina and Rest of South America)
   Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

What are the key strengths of the Onychomycosis drug market in 2025?

The increasing prevalence of onychomycosis globally, along with the growing awareness about fungal infections, strengthens the market. Advancements in antifungal drug development and increased availability of effective treatments contribute to market growth. Furthermore, the expansion of diagnostic techniques and improved patient access to healthcare will boost the adoption of onychomycosis treatments.

What are the main weaknesses in the Onychomycosis drug market in 2025?

The market faces challenges such as high treatment costs, especially for newer antifungal agents, which can limit accessibility for a broader patient base. Additionally, the treatment duration for onychomycosis can be long, reducing patient adherence to prescribed therapies. There is also the issue of recurrence in some cases, which could affect patient outcomes and confidence in available treatments.

What opportunities are expected for the Onychomycosis drug market by 2025?

The market presents opportunities through the introduction of novel drug formulations with better efficacy, shorter treatment courses, and fewer side effects. Increasing research into combination therapies, as well as personalized medicine approaches, could improve treatment outcomes. The growing demand for over-the-counter antifungal products and the expansion of e-commerce platforms also present opportunities for market growth.

What threats could hinder the growth of the Onychomycosis drug market in 2025?

Competitive pressures from generic drugs, which offer lower-cost alternatives, may limit the revenue potential for branded treatments. Additionally, regulatory hurdles and the slow pace of approval for new drugs can delay market entry. The potential for resistance to existing antifungal agents could also pose a threat, driving the need for more innovation in drug development.

What political factors will impact the Onychomycosis drug market in 2025?

Regulatory policies and government healthcare spending will play a significant role in shaping the market. Government approval processes and the pace at which new drugs are cleared for use can impact the introduction of innovative treatments. Additionally, healthcare policies related to drug reimbursement can influence the affordability and accessibility of treatments, particularly in emerging markets.

How will economic factors affect the Onychomycosis drug market by 2025?

Economic conditions such as healthcare budgets, income levels, and insurance coverage will influence the affordability and adoption of onychomycosis treatments. In high-income countries, people are more likely to afford newer, innovative treatments, while in low-income regions, there may be a preference for generic or over-the-counter options. Fluctuations in global economies may also affect the cost of drug production and distribution.

What social trends could impact the Onychomycosis drug market by 2025?

The increasing awareness of fungal infections, especially in older populations and those with compromised immune systems, is driving demand for effective treatments. As people become more health-conscious and focused on hygiene and self-care, the prevalence of onychomycosis is expected to remain significant. Social acceptance and the normalization of medical treatment for such conditions could help reduce stigma, encouraging more individuals to seek care.

How will technological advancements influence the Onychomycosis drug market in 2025?

Technological advancements in diagnostics, such as the development of more efficient and accurate testing for fungal infections, will drive earlier detection and treatment. The growth of telemedicine and digital healthcare platforms can also make treatment options more accessible, especially in remote areas. Additionally, innovations in drug delivery systems and the development of novel antifungal agents will enhance treatment effectiveness and patient compliance.

What environmental factors could impact the Onychomycosis drug market in 2025?

Climate change and global warming could influence the prevalence of fungal infections, as warmer and more humid conditions may create an environment conducive to fungal growth, potentially increasing the demand for treatments. Additionally, environmental sustainability efforts, such as eco-friendly packaging and production methods, could impact the manufacturing processes of onychomycosis drugs.

What legal factors will affect the Onychomycosis drug market by 2025?

Intellectual property laws, such as patents on new antifungal agents, will affect market competition and drug pricing. Strict regulatory standards and guidelines for drug approval may affect the speed of new product introductions. Legal frameworks governing drug safety and efficacy will also ensure that the treatments entering the market are safe for widespread use, influencing both patient trust and market adoption.

Who are the suppliers in the Onychomycosis drug market in 2025?

The suppliers in the Onychomycosis drug market include pharmaceutical companies that manufacture antifungal treatments, raw material providers, and biotechnology firms developing new drug formulations. Suppliers also include research and development institutions that contribute to innovation in drug therapies and drug delivery systems.

What are the inputs into the Onychomycosis drug market in 2025?

Key inputs include active pharmaceutical ingredients (APIs) for antifungal treatments, raw materials for drug production, advanced research data, and clinical trial results. Inputs also consist of regulatory approvals, distribution channels, and healthcare infrastructure necessary for reaching patients, as well as consumer demand for effective onychomycosis treatments.

What are the processes involved in the Onychomycosis drug market in 2025?

Processes include drug discovery and development, clinical testing, regulatory approval, manufacturing, and distribution of onychomycosis treatments. Post-market surveillance, marketing strategies, and patient education are critical steps in ensuring widespread adoption and adherence to prescribed therapies.

Who are the customers in the Onychomycosis drug market in 2025?

The customers include healthcare providers, such as dermatologists, general practitioners, and pharmacies, who prescribe and distribute the drugs. End-users or patients suffering from onychomycosis—both in the general population and those with underlying conditions such as diabetes—are the final consumers of these products.

What are the outputs of the Onychomycosis drug market in 2025?

The outputs include various antifungal drug products, ranging from topical treatments like creams, ointments, and lacquers to systemic oral medications. The market also outputs data on treatment effectiveness, patient outcomes, and safety profiles. Additionally, the market produces research findings that can lead to further innovations in onychomycosis treatment.

How strong is the threat of new entrants in the Onychomycosis drug market in 2025?

The threat of new entrants is moderate. While the onychomycosis drug market offers growth potential, the high costs associated with research and development, regulatory hurdles, and the need for specialized expertise create barriers to entry. Established pharmaceutical companies with strong intellectual property rights dominate, making it challenging for new players to enter and compete.

What is the bargaining power of suppliers in the Onychomycosis drug market in 2025?

The bargaining power of suppliers is moderate. While there are a limited number of suppliers for certain active ingredients, the competition in the pharmaceutical manufacturing sector helps keep supplier power in check. However, specialized ingredients and advanced drug formulations might give specific suppliers some leverage over pricing.

What is the bargaining power of buyers in the Onychomycosis drug market in 2025?

The bargaining power of buyers is moderate to high, particularly in developed markets. Patients and healthcare providers have access to a range of treatment options, including generic antifungals. As more over-the-counter products and alternative therapies become available, buyers can demand better pricing, and insurance companies may exert influence over drug choices based on cost-effectiveness.

What is the threat of substitute products in the Onychomycosis drug market in 2025?

The threat of substitutes is moderate. Over-the-counter antifungal treatments and alternative therapies such as laser treatments or home remedies present substitutes to prescription drugs. However, the efficacy and safety of prescription medications still hold a strong position, particularly for severe cases, meaning the market for prescription treatments remains substantial.

How intense is the competitive rivalry in the Onychomycosis drug market in 2025?

The competitive rivalry is high. Numerous established pharmaceutical companies and biotech firms are involved in developing and marketing antifungal treatments. With an increasing focus on improving treatment efficacy, minimizing side effects, and reducing treatment durations, companies are constantly innovating, leading to a highly competitive landscape. This rivalry is further fueled by the growing demand for more effective and convenient treatments.

What are the key upstream factors influencing the Onychomycosis drug market in 2025?

Upstream factors include the availability of raw materials for the production of antifungal medications, such as active pharmaceutical ingredients (APIs) and excipients. Research and development investment is another critical upstream factor, as innovation in drug formulations and delivery methods will drive the development of more effective treatments. Additionally, the regulatory environment governing the approval of new drugs plays a significant role in shaping the market.

How does the supply chain for Onychomycosis drug production operate in 2025?

The supply chain for Onychomycosis drug production begins with the sourcing of high-quality raw materials, including APIs, which are often sourced from specialized suppliers. These ingredients are then processed and manufactured into finished drugs, either in oral or topical forms. Manufacturers must adhere to strict regulatory guidelines for production and distribution. The supply chain also involves partnerships with distribution networks that ensure timely delivery to healthcare providers and pharmacies.

What are the challenges faced by upstream players in the Onychomycosis drug market in 2025?

Upstream players face challenges related to the sourcing and quality control of raw materials, particularly with specialized APIs that are critical for effective treatments. The regulatory burden can be heavy, as companies must ensure compliance with international standards, which can delay product development and increase costs. Additionally, there is pressure to innovate, as new drug delivery systems or combination therapies become key to gaining a competitive edge in the market.

How do research and development (R&D) activities impact the upstream side of the Onychomycosis drug market?

R&D activities are vital for upstream growth in the Onychomycosis drug market, as they lead to the development of new, more effective antifungal treatments and innovative drug delivery methods. The success of R&D initiatives can significantly impact the availability and diversity of treatment options, which influences market competition and demand. However, R&D efforts require significant investment and can face long timelines due to clinical testing and regulatory approval processes.

What role do regulatory bodies play in the upstream side of the Onychomycosis drug market?

Regulatory bodies such as the FDA, EMA, and other national health authorities play a critical role in shaping the upstream drug market. They establish guidelines for clinical trials, drug approval processes, and manufacturing standards, ensuring the safety and efficacy of onychomycosis treatments. Regulatory decisions can impact the timeline and cost of bringing a drug to market, influencing the overall strategy of upstream players.

What are the key midstream factors impacting the Onychomycosis drug market in 2025?

Midstream factors primarily involve the manufacturing processes and the logistics of distributing antifungal drugs. The availability of advanced production technologies, quality control measures, and cost-effective manufacturing are essential for maintaining drug supply. Distribution networks, including wholesalers, pharmacies, and healthcare providers, also play a crucial role in making the drugs accessible to patients across regions.

How do production capabilities affect the Onychomycosis drug market in 2025?

Production capabilities significantly impact the availability and cost of onychomycosis treatments. The efficiency of manufacturing facilities, the scale of production, and the ability to meet regulatory standards are key. Increased automation and streamlined production processes can help reduce costs and improve drug availability, especially as demand for newer treatments rises.

What are the distribution channels in the Onychomycosis drug market in 2025?

The distribution channels for onychomycosis drugs include wholesale distributors, retail pharmacies, hospitals, and dermatology clinics. Additionally, online pharmaceutical platforms and e-commerce are becoming increasingly important as they provide wider access, especially in remote areas. The role of direct-to-patient delivery services is also growing as telemedicine and digital healthcare platforms become more integrated.

What are the logistical challenges faced by midstream players in the Onychomycosis drug market?

Midstream players face challenges such as maintaining a consistent supply of drugs, especially when dealing with complex or specialized treatments. Cold chain logistics can be a concern for certain topical or injectable treatments. Additionally, ensuring that drugs are available at the right time and location, while also managing storage conditions and expiration dates, can add to the operational complexity.

How do regulatory and quality control requirements affect the midstream operations in the Onychomycosis drug market?

Regulatory and quality control standards heavily influence midstream operations by setting guidelines for drug manufacturing, storage, and distribution. Compliance with Good Manufacturing Practices (GMP) is crucial to ensuring drug safety and effectiveness. Any deviations from these standards can result in product recalls, delays, or reputational damage, making regulatory adherence a critical consideration for midstream stakeholders.

What are the key downstream factors affecting the Onychomycosis drug market in 2025?

Downstream factors include patient access to treatment, healthcare provider prescribing patterns, and the effectiveness of marketing strategies. Patient awareness and education about onychomycosis also play a key role in demand. Additionally, insurance coverage and reimbursement policies significantly impact treatment affordability and accessibility.

How do healthcare providers influence the Onychomycosis drug market in 2025?

Healthcare providers, such as dermatologists and general practitioners, are key in prescribing the appropriate antifungal treatments. Their choice of therapy is influenced by the efficacy, safety, and convenience of available treatments. As treatment guidelines evolve and new drugs enter the market, providers play a critical role in determining which therapies are most widely adopted.

What impact does patient behavior have on the Onychomycosis drug market in 2025?

Patient behavior, including adherence to treatment regimens, directly affects the success of onychomycosis therapies. Long treatment durations can lead to non-compliance, especially for oral medications. Awareness campaigns and patient education will be crucial in encouraging consistent use of prescribed treatments and reducing recurrence rates.

How do marketing and advertising strategies impact the Onychomycosis drug market in 2025?

Marketing and advertising play an important role in influencing consumer choice, especially as new treatments become available. Pharmaceutical companies are increasingly focusing on digital marketing and direct-to-consumer strategies, highlighting the benefits of newer, more effective treatments. Effective campaigns can raise awareness, educate patients about the condition, and drive demand for specific drugs.

What role does insurance and reimbursement play in the downstream side of the Onychomycosis drug market?

Insurance coverage and reimbursement policies are critical for ensuring that onychomycosis treatments are affordable to a wide patient base. In many markets, drugs that are not covered by insurance can be prohibitively expensive, limiting access to certain therapies. Reimbursement policies that prioritize cost-effective treatments and make newer therapies accessible will play a significant role in shaping market dynamics.

Chapter 1, to describe Onychomycosis (Tinea Unguium) Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Onychomycosis (Tinea Unguium) Drug, with revenue, gross margin and global market share of Onychomycosis (Tinea Unguium) Drug from 2018 to 2023.
Chapter 3, the Onychomycosis (Tinea Unguium) Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Onychomycosis (Tinea Unguium) Drug market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Onychomycosis (Tinea Unguium) Drug.
Chapter 13, to describe Onychomycosis (Tinea Unguium) Drug research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of Onychomycosis (Tinea Unguium) Drug
   1.2 Market Estimation Caveats and Base Year
   1.3 Classification of Onychomycosis (Tinea Unguium) Drug by Type
       1.3.1 Overview: Global Onychomycosis (Tinea Unguium) Drug Market Size by Type: 2018 Versus 2022 Versus 2029
       1.3.2 Global Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Type in 2022
       1.3.3 Oral Medication
       1.3.4 External Medicine
   1.4 Global Onychomycosis (Tinea Unguium) Drug Market by Application
       1.4.1 Overview: Global Onychomycosis (Tinea Unguium) Drug Market Size by Application: 2018 Versus 2022 Versus 2029
       1.4.2 Age under 18
       1.4.3 Age 18-50
       1.4.4 Age above 50
   1.5 Global Onychomycosis (Tinea Unguium) Drug Market Size & Forecast
   1.6 Global Onychomycosis (Tinea Unguium) Drug Market Size and Forecast by Region
       1.6.1 Global Onychomycosis (Tinea Unguium) Drug Market Size by Region: 2018 VS 2022 VS 2029
       1.6.2 Global Onychomycosis (Tinea Unguium) Drug Market Size by Region, (2018-2029)
       1.6.3 North America Onychomycosis (Tinea Unguium) Drug Market Size and Prospect (2018-2029)
       1.6.4 Europe Onychomycosis (Tinea Unguium) Drug Market Size and Prospect (2018-2029)
       1.6.5 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size and Prospect (2018-2029)
       1.6.6 South America Onychomycosis (Tinea Unguium) Drug Market Size and Prospect (2018-2029)
       1.6.7 Middle East and Africa Onychomycosis (Tinea Unguium) Drug Market Size and Prospect (2018-2029)

2 Company Profiles

   2.1 Pfizer
       2.1.1 Pfizer Details
       2.1.2 Pfizer Major Business
       2.1.3 Pfizer Onychomycosis (Tinea Unguium) Drug Product and Solutions
       2.1.4 Pfizer Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 Pfizer Recent Developments and Future Plans
   2.2 Yangtze River
       2.2.1 Yangtze River Details
       2.2.2 Yangtze River Major Business
       2.2.3 Yangtze River Onychomycosis (Tinea Unguium) Drug Product and Solutions
       2.2.4 Yangtze River Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.2.5 Yangtze River Recent Developments and Future Plans
   2.3 Torrent Pharma
       2.3.1 Torrent Pharma Details
       2.3.2 Torrent Pharma Major Business
       2.3.3 Torrent Pharma Onychomycosis (Tinea Unguium) Drug Product and Solutions
       2.3.4 Torrent Pharma Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.3.5 Torrent Pharma Recent Developments and Future Plans
   2.4 J&J
       2.4.1 J&J Details
       2.4.2 J&J Major Business
       2.4.3 J&J Onychomycosis (Tinea Unguium) Drug Product and Solutions
       2.4.4 J&J Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.4.5 J&J Recent Developments and Future Plans
   2.5 Chengdu Brilliant
       2.5.1 Chengdu Brilliant Details
       2.5.2 Chengdu Brilliant Major Business
       2.5.3 Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Product and Solutions
       2.5.4 Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.5.5 Chengdu Brilliant Recent Developments and Future Plans
   2.6 Novartis
       2.6.1 Novartis Details
       2.6.2 Novartis Major Business
       2.6.3 Novartis Onychomycosis (Tinea Unguium) Drug Product and Solutions
       2.6.4 Novartis Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.6.5 Novartis Recent Developments and Future Plans
   2.7 Qilu Pharmaceutical
       2.7.1 Qilu Pharmaceutical Details
       2.7.2 Qilu Pharmaceutical Major Business
       2.7.3 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product and Solutions
       2.7.4 Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.7.5 Qilu Pharmaceutical Recent Developments and Future Plans
   2.8 Xiuzheng Pharmaceutical
       2.8.1 Xiuzheng Pharmaceutical Details
       2.8.2 Xiuzheng Pharmaceutical Major Business
       2.8.3 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product and Solutions
       2.8.4 Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.8.5 Xiuzheng Pharmaceutical Recent Developments and Future Plans
   2.9 Hubei Hengan
       2.9.1 Hubei Hengan Details
       2.9.2 Hubei Hengan Major Business
       2.9.3 Hubei Hengan Onychomycosis (Tinea Unguium) Drug Product and Solutions
       2.9.4 Hubei Hengan Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.9.5 Hubei Hengan Recent Developments and Future Plans
   2.10 TARO 
       2.10.1 TARO Details
       2.10.2 TARO Major Business
       2.10.3 TARO Onychomycosis (Tinea Unguium) Drug Product and Solutions
       2.10.4 TARO Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.10.5 TARO Recent Developments and Future Plans
   2.11 Perrigo
       2.11.1 Perrigo Details
       2.11.2 Perrigo Major Business
       2.11.3 Perrigo Onychomycosis (Tinea Unguium) Drug Product and Solutions
       2.11.4 Perrigo Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.11.5 Perrigo Recent Developments and Future Plans
   2.12 Galderma pharm
       2.12.1 Galderma pharm Details
       2.12.2 Galderma pharm Major Business
       2.12.3 Galderma pharm Onychomycosis (Tinea Unguium) Drug Product and Solutions
       2.12.4 Galderma pharm Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.12.5 Galderma pharm Recent Developments and Future Plans
   2.13 Zhejiang Deyer
       2.13.1 Zhejiang Deyer Details
       2.13.2 Zhejiang Deyer Major Business
       2.13.3 Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Product and Solutions
       2.13.4 Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.13.5 Zhejiang Deyer Recent Developments and Future Plans
   2.14 Valeant Pharma
       2.14.1 Valeant Pharma Details
       2.14.2 Valeant Pharma Major Business
       2.14.3 Valeant Pharma Onychomycosis (Tinea Unguium) Drug Product and Solutions
       2.14.4 Valeant Pharma Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.14.5 Valeant Pharma Recent Developments and Future Plans
   2.15 Moberg
       2.15.1 Moberg Details
       2.15.2 Moberg Major Business
       2.15.3 Moberg Onychomycosis (Tinea Unguium) Drug Product and Solutions
       2.15.4 Moberg Onychomycosis (Tinea Unguium) Drug Revenue, Gross Margin and Market Share (2018-2023)
       2.15.5 Moberg Recent Developments and Future Plans

3 Market Competition, by Players

   3.1 Global Onychomycosis (Tinea Unguium) Drug Revenue and Share by Players (2018-2023)
   3.2 Market Share Analysis (2022)
       3.2.1 Market Share of Onychomycosis (Tinea Unguium) Drug by Company Revenue
       3.2.2 Top 3 Onychomycosis (Tinea Unguium) Drug Players Market Share in 2022
       3.2.3 Top 6 Onychomycosis (Tinea Unguium) Drug Players Market Share in 2022
   3.3 Onychomycosis (Tinea Unguium) Drug Market: Overall Company Footprint Analysis
       3.3.1 Onychomycosis (Tinea Unguium) Drug Market: Region Footprint
       3.3.2 Onychomycosis (Tinea Unguium) Drug Market: Company Product Type Footprint
       3.3.3 Onychomycosis (Tinea Unguium) Drug Market: Company Product Application Footprint
   3.4 New Market Entrants and Barriers to Market Entry
   3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

   4.1 Global Onychomycosis (Tinea Unguium) Drug Consumption Value and Market Share by Type (2018-2023)
   4.2 Global Onychomycosis (Tinea Unguium) Drug Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

   5.1 Global Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Application (2018-2023)
   5.2 Global Onychomycosis (Tinea Unguium) Drug Market Forecast by Application (2024-2029)

6 North America

   6.1 North America Onychomycosis (Tinea Unguium) Drug Consumption Value by Type (2018-2029)
   6.2 North America Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2018-2029)
   6.3 North America Onychomycosis (Tinea Unguium) Drug Market Size by Country
       6.3.1 North America Onychomycosis (Tinea Unguium) Drug Consumption Value by Country (2018-2029)
       6.3.2 United States Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)
       6.3.3 Canada Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)
       6.3.4 Mexico Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)

7 Europe

   7.1 Europe Onychomycosis (Tinea Unguium) Drug Consumption Value by Type (2018-2029)
   7.2 Europe Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2018-2029)
   7.3 Europe Onychomycosis (Tinea Unguium) Drug Market Size by Country
       7.3.1 Europe Onychomycosis (Tinea Unguium) Drug Consumption Value by Country (2018-2029)
       7.3.2 Germany Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)
       7.3.3 France Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)
       7.3.4 United Kingdom Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)
       7.3.5 Russia Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)
       7.3.6 Italy Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)

8 Asia-Pacific

   8.1 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Consumption Value by Type (2018-2029)
   8.2 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2018-2029)
   8.3 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Market Size by Region
       8.3.1 Asia-Pacific Onychomycosis (Tinea Unguium) Drug Consumption Value by Region (2018-2029)
       8.3.2 China Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)
       8.3.3 Japan Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)
       8.3.4 South Korea Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)
       8.3.5 India Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)
       8.3.6 Southeast Asia Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)
       8.3.7 Australia Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)

9 South America

   9.1 South America Onychomycosis (Tinea Unguium) Drug Consumption Value by Type (2018-2029)
   9.2 South America Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2018-2029)
   9.3 South America Onychomycosis (Tinea Unguium) Drug Market Size by Country
       9.3.1 South America Onychomycosis (Tinea Unguium) Drug Consumption Value by Country (2018-2029)
       9.3.2 Brazil Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)
       9.3.3 Argentina Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)

10 Middle East & Africa

   10.1 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Consumption Value by Type (2018-2029)
   10.2 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2018-2029)
   10.3 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Market Size by Country
       10.3.1 Middle East & Africa Onychomycosis (Tinea Unguium) Drug Consumption Value by Country (2018-2029)
       10.3.2 Turkey Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)
       10.3.3 Saudi Arabia Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)
       10.3.4 UAE Onychomycosis (Tinea Unguium) Drug Market Size and Forecast (2018-2029)

11 Market Dynamics

   11.1 Onychomycosis (Tinea Unguium) Drug Market Drivers
   11.2 Onychomycosis (Tinea Unguium) Drug Market Restraints
   11.3 Onychomycosis (Tinea Unguium) Drug Trends Analysis
   11.4 Porters Five Forces Analysis
       11.4.1 Threat of New Entrants
       11.4.2 Bargaining Power of Suppliers
       11.4.3 Bargaining Power of Buyers
       11.4.4 Threat of Substitutes
       11.4.5 Competitive Rivalry
   11.5 Influence of COVID-19 and Russia-Ukraine War
       11.5.1 Influence of COVID-19
       11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

   12.1 Onychomycosis (Tinea Unguium) Drug Industry Chain
   12.2 Onychomycosis (Tinea Unguium) Drug Upstream Analysis
   12.3 Onychomycosis (Tinea Unguium) Drug Midstream Analysis
   12.4 Onychomycosis (Tinea Unguium) Drug Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

   14.1 Methodology
   14.2 Research Process and Data Source
   14.3 Disclaimer

List of Tables

   Table 1. Global Onychomycosis (Tinea Unguium) Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Table 2. Global Onychomycosis (Tinea Unguium) Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Table 3. Global Onychomycosis (Tinea Unguium) Drug Consumption Value by Region (2018-2023) & (USD Million)
   Table 4. Global Onychomycosis (Tinea Unguium) Drug Consumption Value by Region (2024-2029) & (USD Million)
   Table 5. Pfizer Company Information, Head Office, and Major Competitors
   Table 6. Pfizer Major Business
   Table 7. Pfizer Onychomycosis (Tinea Unguium) Drug Product and Solutions
   Table 8. Pfizer Onychomycosis (Tinea Unguium) Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 9. Pfizer Recent Developments and Future Plans
   Table 10. Yangtze River Company Information, Head Office, and Major Competitors
   Table 11. Yangtze River Major Business
   Table 12. Yangtze River Onychomycosis (Tinea Unguium) Drug Product and Solutions
   Table 13. Yangtze River Onychomycosis (Tinea Unguium) Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 14. Yangtze River Recent Developments and Future Plans
   Table 15. Torrent Pharma Company Information, Head Office, and Major Competitors
   Table 16. Torrent Pharma Major Business
   Table 17. Torrent Pharma Onychomycosis (Tinea Unguium) Drug Product and Solutions
   Table 18. Torrent Pharma Onychomycosis (Tinea Unguium) Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 19. Torrent Pharma Recent Developments and Future Plans
   Table 20. J&J Company Information, Head Office, and Major Competitors
   Table 21. J&J Major Business
   Table 22. J&J Onychomycosis (Tinea Unguium) Drug Product and Solutions
   Table 23. J&J Onychomycosis (Tinea Unguium) Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 24. J&J Recent Developments and Future Plans
   Table 25. Chengdu Brilliant Company Information, Head Office, and Major Competitors
   Table 26. Chengdu Brilliant Major Business
   Table 27. Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Product and Solutions
   Table 28. Chengdu Brilliant Onychomycosis (Tinea Unguium) Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 29. Chengdu Brilliant Recent Developments and Future Plans
   Table 30. Novartis Company Information, Head Office, and Major Competitors
   Table 31. Novartis Major Business
   Table 32. Novartis Onychomycosis (Tinea Unguium) Drug Product and Solutions
   Table 33. Novartis Onychomycosis (Tinea Unguium) Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 34. Novartis Recent Developments and Future Plans
   Table 35. Qilu Pharmaceutical Company Information, Head Office, and Major Competitors
   Table 36. Qilu Pharmaceutical Major Business
   Table 37. Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product and Solutions
   Table 38. Qilu Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 39. Qilu Pharmaceutical Recent Developments and Future Plans
   Table 40. Xiuzheng Pharmaceutical Company Information, Head Office, and Major Competitors
   Table 41. Xiuzheng Pharmaceutical Major Business
   Table 42. Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Product and Solutions
   Table 43. Xiuzheng Pharmaceutical Onychomycosis (Tinea Unguium) Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 44. Xiuzheng Pharmaceutical Recent Developments and Future Plans
   Table 45. Hubei Hengan Company Information, Head Office, and Major Competitors
   Table 46. Hubei Hengan Major Business
   Table 47. Hubei Hengan Onychomycosis (Tinea Unguium) Drug Product and Solutions
   Table 48. Hubei Hengan Onychomycosis (Tinea Unguium) Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 49. Hubei Hengan Recent Developments and Future Plans
   Table 50. TARO Company Information, Head Office, and Major Competitors
   Table 51. TARO Major Business
   Table 52. TARO Onychomycosis (Tinea Unguium) Drug Product and Solutions
   Table 53. TARO Onychomycosis (Tinea Unguium) Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 54. TARO Recent Developments and Future Plans
   Table 55. Perrigo Company Information, Head Office, and Major Competitors
   Table 56. Perrigo Major Business
   Table 57. Perrigo Onychomycosis (Tinea Unguium) Drug Product and Solutions
   Table 58. Perrigo Onychomycosis (Tinea Unguium) Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 59. Perrigo Recent Developments and Future Plans
   Table 60. Galderma pharm Company Information, Head Office, and Major Competitors
   Table 61. Galderma pharm Major Business
   Table 62. Galderma pharm Onychomycosis (Tinea Unguium) Drug Product and Solutions
   Table 63. Galderma pharm Onychomycosis (Tinea Unguium) Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 64. Galderma pharm Recent Developments and Future Plans
   Table 65. Zhejiang Deyer Company Information, Head Office, and Major Competitors
   Table 66. Zhejiang Deyer Major Business
   Table 67. Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Product and Solutions
   Table 68. Zhejiang Deyer Onychomycosis (Tinea Unguium) Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 69. Zhejiang Deyer Recent Developments and Future Plans
   Table 70. Valeant Pharma Company Information, Head Office, and Major Competitors
   Table 71. Valeant Pharma Major Business
   Table 72. Valeant Pharma Onychomycosis (Tinea Unguium) Drug Product and Solutions
   Table 73. Valeant Pharma Onychomycosis (Tinea Unguium) Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 74. Valeant Pharma Recent Developments and Future Plans
   Table 75. Moberg Company Information, Head Office, and Major Competitors
   Table 76. Moberg Major Business
   Table 77. Moberg Onychomycosis (Tinea Unguium) Drug Product and Solutions
   Table 78. Moberg Onychomycosis (Tinea Unguium) Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 79. Moberg Recent Developments and Future Plans
   Table 80. Global Onychomycosis (Tinea Unguium) Drug Revenue (USD Million) by Players (2018-2023)
   Table 81. Global Onychomycosis (Tinea Unguium) Drug Revenue Share by Players (2018-2023)
   Table 82. Breakdown of Onychomycosis (Tinea Unguium) Drug by Company Type (Tier 1, Tier 2, and Tier 3)
   Table 83. Market Position of Players in Onychomycosis (Tinea Unguium) Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
   Table 84. Head Office of Key Onychomycosis (Tinea Unguium) Drug Players
   Table 85. Onychomycosis (Tinea Unguium) Drug Market: Company Product Type Footprint
   Table 86. Onychomycosis (Tinea Unguium) Drug Market: Company Product Application Footprint
   Table 87. Onychomycosis (Tinea Unguium) Drug New Market Entrants and Barriers to Market Entry
   Table 88. Onychomycosis (Tinea Unguium) Drug Mergers, Acquisition, Agreements, and Collaborations
   Table 89. Global Onychomycosis (Tinea Unguium) Drug Consumption Value (USD Million) by Type (2018-2023)
   Table 90. Global Onychomycosis (Tinea Unguium) Drug Consumption Value Share by Type (2018-2023)
   Table 91. Global Onychomycosis (Tinea Unguium) Drug Consumption Value Forecast by Type (2024-2029)
   Table 92. Global Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2018-2023)
   Table 93. Global Onychomycosis (Tinea Unguium) Drug Consumption Value Forecast by Application (2024-2029)
   Table 94. North America Onychomycosis (Tinea Unguium) Drug Consumption Value by Type (2018-2023) & (USD Million)
   Table 95. North America Onychomycosis (Tinea Unguium) Drug Consumption Value by Type (2024-2029) & (USD Million)
   Table 96. North America Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2018-2023) & (USD Million)
   Table 97. North America Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2024-2029) & (USD Million)
   Table 98. North America Onychomycosis (Tinea Unguium) Drug Consumption Value by Country (2018-2023) & (USD Million)
   Table 99. North America Onychomycosis (Tinea Unguium) Drug Consumption Value by Country (2024-2029) & (USD Million)
   Table 100. Europe Onychomycosis (Tinea Unguium) Drug Consumption Value by Type (2018-2023) & (USD Million)
   Table 101. Europe Onychomycosis (Tinea Unguium) Drug Consumption Value by Type (2024-2029) & (USD Million)
   Table 102. Europe Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2018-2023) & (USD Million)
   Table 103. Europe Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2024-2029) & (USD Million)
   Table 104. Europe Onychomycosis (Tinea Unguium) Drug Consumption Value by Country (2018-2023) & (USD Million)
   Table 105. Europe Onychomycosis (Tinea Unguium) Drug Consumption Value by Country (2024-2029) & (USD Million)
   Table 106. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Consumption Value by Type (2018-2023) & (USD Million)
   Table 107. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Consumption Value by Type (2024-2029) & (USD Million)
   Table 108. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2018-2023) & (USD Million)
   Table 109. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2024-2029) & (USD Million)
   Table 110. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Consumption Value by Region (2018-2023) & (USD Million)
   Table 111. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Consumption Value by Region (2024-2029) & (USD Million)
   Table 112. South America Onychomycosis (Tinea Unguium) Drug Consumption Value by Type (2018-2023) & (USD Million)
   Table 113. South America Onychomycosis (Tinea Unguium) Drug Consumption Value by Type (2024-2029) & (USD Million)
   Table 114. South America Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2018-2023) & (USD Million)
   Table 115. South America Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2024-2029) & (USD Million)
   Table 116. South America Onychomycosis (Tinea Unguium) Drug Consumption Value by Country (2018-2023) & (USD Million)
   Table 117. South America Onychomycosis (Tinea Unguium) Drug Consumption Value by Country (2024-2029) & (USD Million)
   Table 118. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Consumption Value by Type (2018-2023) & (USD Million)
   Table 119. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Consumption Value by Type (2024-2029) & (USD Million)
   Table 120. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2018-2023) & (USD Million)
   Table 121. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Consumption Value by Application (2024-2029) & (USD Million)
   Table 122. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Consumption Value by Country (2018-2023) & (USD Million)
   Table 123. Middle East & Africa Onychomycosis (Tinea Unguium) Drug Consumption Value by Country (2024-2029) & (USD Million)
   Table 124. Onychomycosis (Tinea Unguium) Drug Raw Material
   Table 125. Key Suppliers of Onychomycosis (Tinea Unguium) Drug Raw Materials

List of Figures

   Figure 1. Onychomycosis (Tinea Unguium) Drug Picture
   Figure 2. Global Onychomycosis (Tinea Unguium) Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Type in 2022
   Figure 4. Oral Medication
   Figure 5. External Medicine
   Figure 6. Global Onychomycosis (Tinea Unguium) Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 7. Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Application in 2022
   Figure 8. Age under 18 Picture
   Figure 9. Age 18-50 Picture
   Figure 10. Age above 50 Picture
   Figure 11. Global Onychomycosis (Tinea Unguium) Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 12. Global Onychomycosis (Tinea Unguium) Drug Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 13. Global Market Onychomycosis (Tinea Unguium) Drug Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
   Figure 14. Global Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Region (2018-2029)
   Figure 15. Global Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Region in 2022
   Figure 16. North America Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 17. Europe Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 18. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 19. South America Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 20. Middle East and Africa Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 21. Global Onychomycosis (Tinea Unguium) Drug Revenue Share by Players in 2022
   Figure 22. Onychomycosis (Tinea Unguium) Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
   Figure 23. Global Top 3 Players Onychomycosis (Tinea Unguium) Drug Market Share in 2022
   Figure 24. Global Top 6 Players Onychomycosis (Tinea Unguium) Drug Market Share in 2022
   Figure 25. Global Onychomycosis (Tinea Unguium) Drug Consumption Value Share by Type (2018-2023)
   Figure 26. Global Onychomycosis (Tinea Unguium) Drug Market Share Forecast by Type (2024-2029)
   Figure 27. Global Onychomycosis (Tinea Unguium) Drug Consumption Value Share by Application (2018-2023)
   Figure 28. Global Onychomycosis (Tinea Unguium) Drug Market Share Forecast by Application (2024-2029)
   Figure 29. North America Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Type (2018-2029)
   Figure 30. North America Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Application (2018-2029)
   Figure 31. North America Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Country (2018-2029)
   Figure 32. United States Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 33. Canada Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 34. Mexico Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 35. Europe Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Type (2018-2029)
   Figure 36. Europe Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Application (2018-2029)
   Figure 37. Europe Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Country (2018-2029)
   Figure 38. Germany Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 39. France Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 40. United Kingdom Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 41. Russia Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 42. Italy Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 43. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Type (2018-2029)
   Figure 44. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Application (2018-2029)
   Figure 45. Asia-Pacific Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Region (2018-2029)
   Figure 46. China Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 47. Japan Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 48. South Korea Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 49. India Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 50. Southeast Asia Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 51. Australia Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 52. South America Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Type (2018-2029)
   Figure 53. South America Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Application (2018-2029)
   Figure 54. South America Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Country (2018-2029)
   Figure 55. Brazil Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 56. Argentina Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 57. Middle East and Africa Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Type (2018-2029)
   Figure 58. Middle East and Africa Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Application (2018-2029)
   Figure 59. Middle East and Africa Onychomycosis (Tinea Unguium) Drug Consumption Value Market Share by Country (2018-2029)
   Figure 60. Turkey Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 61. Saudi Arabia Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 62. UAE Onychomycosis (Tinea Unguium) Drug Consumption Value (2018-2029) & (USD Million)
   Figure 63. Onychomycosis (Tinea Unguium) Drug Market Drivers
   Figure 64. Onychomycosis (Tinea Unguium) Drug Market Restraints
   Figure 65. Onychomycosis (Tinea Unguium) Drug Market Trends
   Figure 66. Porters Five Forces Analysis
   Figure 67. Manufacturing Cost Structure Analysis of Onychomycosis (Tinea Unguium) Drug in 2022
   Figure 68. Manufacturing Process Analysis of Onychomycosis (Tinea Unguium) Drug
   Figure 69. Onychomycosis (Tinea Unguium) Drug Industrial Chain
   Figure 70. Methodology
   Figure 71. Research Process and Data Source